Abstract
Microdosing psychedelics, the repeated use of small doses of substances such as psilocybin and lysergic acid diethylamide, has gained popular and scientific attention in recent years. While some users claim microdosing psychedelics has therapeutic value, to date only a handful of (placebo-controlled) experimental studies in human volunteers have been conducted testing the effects of low doses on physiological, subjective state, and performance measures. This chapter aims to answer, based on the scientific knowledge we have so far, whether microdosing psychedelics has therapeutic potential. Reviewed studies demonstrated that low doses were in general well tolerated. Single doses produced subtle, beneficial effects on selective performance measures and subjective states. The fact that most studies were conducted in small samples of healthy (young) volunteers hampers generalization to other populations. However, the observed cognitive and affective effects might be of help in some psychiatric disorders such as attention-deficit hyperactivity disorder or depression. Future placebo-controlled studies in patient populations are needed to conclude about the (therapeutic) potential of microdosing psychedelics.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abramson HA, Kornetsky C, Jarvik ME, Kaufman MR, Ferguson MW (1955) Lysergic acid diethylamide (Lsd-25): Xi. Content analysis of clinical reactions. J Psychol 40:53–60
Abramson HA, Rolo A (1965) Lysergic acid diethylamide (LSD-25). 38. Comparison with action of methysergide and psilocybin on test subjects. J Asthma Res 3:81–96
Anderson T, Petranker R, Rosenbaum D, Weissman CR, Dinh-Williams LA, Hui K, Hapke E, Farb NAS (2019a) Microdosing psychedelics: personality, mental health, and creativity differences in microdosers. Psychopharmacology 236:731–740
Anderson T, Petranker R, Christopher A, Rosenbaum D, Weissman C, Dinh-Williams L-A, Hui K, Hapke E (2019b) Psychedelic microdosing benefits and challenges: an empirical codebook. Harm Reduct J 16:43
Andersson M, Kjellgren A (2019) Twenty percent better with 20 micrograms? A qualitative study of psychedelic microdosing self-rapports and discussions on YouTube. Harm Reduct J 16:63
Bershad AK, Preller KH, Lee R, Keedy S, Wren-Jarvis J, Bremmer MP, de Wit H (2020) Preliminary report on the effects of a low dose of LSD on resting state amygdalar functional connectivity. Biol Psychiatry Cogn Neurosci Neuroimaging 5(4):461–467
Bershad AK, Schepers ST, Bremmer MP, Lee R, de Wit H (2019) Acute subjective and behavioral effects of microdoses of lysergic acid diethylamide in healthy human volunteers. Biol Psychiatry 86:792–800
Bertino JS Jr, Greenberg HE, Reed MD (2007) American College of Clinical Pharmacology position statement on the use of microdosing in the drug development process. J Clin Pharmacol 47:418+
Boardman WK, Goldstone S, Lhamon WT (1957) Effects of lysergic acid diethylamide (LSD) on the time sense of Normals: a preliminary report. AMA Arch Neurol Psychiatry 78:321–324
Carhart-Harris RL, Goodwin GM (2017) The therapeutic potential of psychedelic drugs: past, present, and future. Neuropsychopharmacology 42:2105–2113
Chi T, Gold JA (2020) A review of emerging therapeutic potential of psychedelic drugs in the treatment of psychiatric illnesses. J Neurol Sci 411:116715
Dolder PC, Schmid Y, Haschke M, Rentsch KM, Liechti ME (2015) Pharmacokinetics and concentration-effect relationship of oral LSD in humans. Int J Neuropsychopharmacol 19:pyv072
Dolder PC, Schmid Y, Steuer AE, Kraemer T, Rentsch KM, Hammann F, Liechti ME (2017) Pharmacokinetics and pharmacodynamics of lysergic acid diethylamide in healthy subjects. Clin Pharmacokinet 56:1219–1230
dos Santos RG, Osório FL, Crippa JAS, Riba J, Zuardi AW, Hallak JEC (2016) Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years. Ther Adv Psychopharmacol 6:193–213
Fadiman J (2017) Microdose research: without approvals, control groups, double-blinds, staff or funding by Dr James Fadiman. In.: Psychedelic Press. 2017XV. Available: https://psychedelicpress.co.uk/blogs/psychedelic-press-blog/microdose-research-james-fadiman
Fadiman J, Korb S (2019) Might microdosing psychedelics be safe and beneficial? An initial exploration. J Psychoactive Drugs 51:118–122
Fadiman, James. 2011. The psychedelic explorer’s guide: safe, therapeutic, and sacred journeys. Rochester, Vt. Park Street Press
Family N, Maillet EL, Williams LTJ, Krediet E, Carhart-Harris RL, Williams TM, Nichols CD, Goble DJ, Raz S (2019) Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers. Psychopharmacology 237(3):841–853
Fuentes JJ, Fonseca F, Elices M, Farré M, Torrens M (2020) Therapeutic use of LSD in psychiatry: a systematic review of randomized-controlled clinical trials. Front Psych 10:943
Garner RC, Lappin G (2006) Commentary. Br J Clin Pharmacol 61:367–370
Gasser P, Holstein D, Michel Y, Doblin R, Yazar-Klosinski B, Passie T, Brenneisen R (2014) Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis 202:513–520
Gasser P, Kirchner K, Passie T (2015) LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: a qualitative study of acute and sustained subjective effects. J Psychopharmacol 29:57–68
Ghose T (2015) Short trip? More people ‘microdosing’ on psychedelics drugs. In Live science. https://www.nbcnews.com/science/weird-science/short-trip-more-people-microdosing-psychedelic-drugs-n390791
Greiner T, Burch NR, Edelberg R (1958) Psychopathology and psychophysiology of minimal LSD-25 dosage; a preliminary dosage-response spectrum. AMA Arch Neurol Psychiatry 79:208–210
Griffiths RR, Johnson MW, Richards WA, Richards BD, McCann U, Jesse R (2011) Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology 218:649–665
Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, Cosimano MP, Klinedinst MA (2016) Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol 30:1181–1197
Hasler F, Grimberg U, Benz MA, Huber T, Vollenweider FX (2004) Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study. Psychopharmacology 172:145–156
Horowitz M (1976) Interview with Albert Hofmann, High Times
Hutten NRPW, Mason NL, Dolder PC, Kuypers KPC (2019a) Motives and side-effects of microdosing with psychedelics among users. Int J Neuropsychopharmacol 22:426–434
Hutten NRPW, Mason NL, Dolder PC, Kuypers KPC (2019b) Self-rated effectiveness of microdosing with psychedelics for mental and physical health problems among microdosers. Front Psychiatry 10:672
Hutten N, Mason NL, Dolder PC, Kuypers KPC (2019c) Self-rated effectiveness of microdosing with psychedelics for mental and physical health problems among microdosers. Front Psych 10:672
Isbell H, Belleville RE, Fraser HF, Wikler A, Logan CR (1956) Studies on lysergic acid diethylamide (LSD-25): I. Effects in former morphine addicts and development of tolerance during chronic intoxication. AMA Arch Neurol Psychiatry 76:468–478
Johnson MW, Griffiths RR (2017) Potential therapeutic effects of psilocybin. Neurotherapeutics 14:734–740
Johnstad PG (2018) Powerful substances in tiny amounts: an interview study of psychedelic microdosing. Nordic Stud Alcohol Drugs 35:39–51
Kuypers KPC, Ng L, Erritzoe D, Knudsen GM, Nichols CD, Nichols DE, Pani L, Soula A, Nutt D (2019) Microdosing psychedelics: more questions than answers? An overview and suggestions for future research. J Psychopharmacol 33:1039–1057
Lea T, Amada N, Jungaberle H, Schecke H, Klein M (2020) Microdosing psychedelics: motivations, subjective effects and harm reduction. Int J Drug Policy 75:102600
Lea T, Amada N, Jungaberle H (2019) Psychedelic microdosing: a Subreddit analysis. J Psychoactive Drugs:1–12
Lee MR (2010) The history of ergot of rye (Claviceps purpurea) III: 1940–80. J R Coll Physicians Edinb 40:77–80
Liechti ME (2017) Modern clinical research on LSD. Neuropsychopharmacology 42:2114–2127
Madsen MK, Fisher PM, Burmester D, Dyssegaard A, Stenbaek DS, Kristiansen S, Johansen SS, Lehel S, Linnet K, Svarer C, Erritzoe D, Ozenne B, Knudsen GM (2019) Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. Neuropsychopharmacology 44:1328–1334
Mason NL, Mischler E, Uthaug MV, Kuypers KPC (2019) Sub-acute effects of psilocybin on empathy, creative thinking, and subjective well-being. J Psychoactive Drugs 51:123–134
McGlothlin W, Cohen S, McGlothlin MS (1967) Long lasting effects of LSD on normals. Arch Gen Psychiatry 17:521–532
Meaux JB, Hester C, Smith B, Shoptaw A (2006) Stimulant medications: a trade-off? The lived experience of adolescents with ADHD. J Spec Pediatr Nurs 11:214–226
Moreno FA, Wiegand CB, Taitano EK, Delgado PL (2006) Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry 67:1735–1740
Nichols DE (2016) Psychedelics. Pharmacol Rev 68:264–355
Osmond H (1957) A review of the clinical effects of psychotomimetic agents. Ann N Y Acad Sci 66:418–434
Passie T (2019) The science of microdosing psychedelics. Psychedelic Press. London, UK
Penn E, Tracy DK (2012) The drugs don’t work? Antidepressants and the current and future pharmacological management of depression. Ther Adv Psychopharmacol 2:179–188
Pokorny T, Duerler P, Seifritz E, Vollenweider FX, Preller KH (2019) LSD acutely impairs working memory, executive functions, and cognitive flexibility, but not risk-based decision-making. Psychol Med 50(13):2255–2264
Pokorny T, Preller KH, Kometer M, Dziobek I, Vollenweider FX (2017) Effect of psilocybin on empathy and moral decision-making. Int J Neuropsychopharmacol 20:747–757
Polito V, Stevenson RJ (2019) A systematic study of microdosing psychedelics. PLoS One 14:e0211023
Predictable SEAU (2006) Side effects of antidepressants: an overview. Cleveland Clin J Med 73:351
Prochazkova L, Lippelt DP, Colzato LS, Kuchar M, Sjoerds Z, Hommel B (2018) Exploring the effect of microdosing psychedelics on creativity in an open-label natural setting. Psychopharmacology 235:3401–3413
Sakloth F, Leggett E, Moerke MJ, Townsend EA, Banks ML, Negus SS (2019) Effects of acute and repeated treatment with serotonin 5-HT2A receptor agonist hallucinogens on intracranial self-stimulation in rats. Exp Clin Psychopharmacol 27:215–226
Studerus E, Kometer M, Hasler F, Vollenweider FX (2011) Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. J Psychopharmacol 25:1434–1452
Tylš F, Páleníček T, Horáček J (2014) Psilocybin – summary of knowledge and new perspectives. Eur Neuropsychopharmacol 24:342–356
Vanderhasselt M-A, De Raedt R, De Paepe A, Aarts K, Otte G, Van Dorpe J, Pourtois G (2014) Abnormal proactive and reactive cognitive control during conflict processing in major depression. J Abnorm Psychol 123:68–80
Webb M, Copes H, Hendricks PS (2019) Narrative identity, rationality, and microdosing classic psychedelics. Int J Drug Policy 70:33–39
Yanakieva S, Polychroni N, Family N, Williams LTJ, Luke DP, Terhune DB (2019) The effects of microdose LSD on time perception: a randomised, double-blind, placebo-controlled trial. Psychopharmacology 236:1159–1170
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Kuypers, K.P.C. (2021). Microdosing Psychedelics as a Promising New Pharmacotherapeutic. In: Schreiber, R. (eds) Modern CNS Drug Discovery . Springer, Cham. https://doi.org/10.1007/978-3-030-62351-7_18
Download citation
DOI: https://doi.org/10.1007/978-3-030-62351-7_18
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-62350-0
Online ISBN: 978-3-030-62351-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)